When what you predicted, preached, and wished are realized, this is good news.

Today’s news is bringing all Prohost predictions into realization, Yes, Kite (KITE) is on its way to be acquired by Gilead (GILD) and yes both stocks have rallied and yes Juno (JUNO) is also rallying on the Kite’s news because both firms are pioneers in the CAR-T Immunotherapy technology and drugs. Rallied also is Bellicum (BLCM), which is also a CAR-T player, but less financed and less known than Kite and Juno.

In the NEWS

As Kite Pharma agreed to be acquired by Gilead for about $11.9 billion, Kite stock jumped 30% to around $179 in early trading and remained around the same price until the time we posted this news. Gilead’s stock is trading at $75.73 up $1.78.

We believe that it is the beginning of a long time rallying for Gilead.

This acquisition establishes Gilead  as one of the three largest leaders in cellular therapy. The other two are Novartis (NVS) and Juno (JUNO).

Being one of the three leaders of what might become the most important cancer treatment, Gilead’s pipeline is now diversified. The company added a cancer program to its pipeline products. As a matter of reality, the added cancer program is the immunotherapy treatment that oncologists expected it will stay and improve and become the standard of care for most cancers.

Prohost Observations

 It is a great choice made by Gilead.

We also do not want to miss telling about Juno’s rally.

JUNO is now trading at $35.98 Up $5.25 at this time.

We congratulate our subscribers who kept these stocks and did not throw in spite of the many negative voices that are singing everywhere on the Internet.

Other important news will be posted later in the day under Today’s Highlights.

Stay Tuned

Prohost Forward-Looking: Material presented here is for informational purposes only. Nothing in this article should be taken as a solicitation to purchase or sell securities. Before buying or selling any stock you should do your own research and reach your own conclusion. Further, these are our ‘opinions’ and we may be wrong. We may have positions in securities mentioned in this article. You should take this into consideration before acting on any advice given in this article. If this makes you uncomfortable, then do not listen to our thoughts and opinions. The contents of this article do not take into consideration your individual investment objectives so consult with your own financial adviser before making an investment decision. Investing includes certain risks including loss of principal.